The company have advised that they will not be pursuing a licensing application for nivolumab from the European Medicines Authority for this indication at this time. Therefore, NICE has decided to suspend this appraisal on its work programme for the time being. As this appraisal has been referred to NICE we will continue to monitor any development and will update interested parties if the situation changes.
 
Status Suspended
Process STA
ID number 1103

Project Team

Project lead Michelle Adhemar

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
16 June 2017 Suspended, The company have advised that they will not be pursuing a licensing application for nivolumab from the European Medicines Authority for this indication at this time. Therefore, NICE has decided to suspend this appraisal on its work programme for the time being. As this appraisal has been referred to NICE we will continue to monitor any development and will update interested parties if the situation changes.
22 July 2016 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance